The artemisinin antimalarials are the cornerstone of current malaria treatment. The
development of artemisinin resistance in Plasmodium falciparum poses a major threat to …

Malaria, which is caused by infection of red blood cells with Plasmodium parasites, can be
fatal in non-immune individuals if left untreated. The recent approval of the pre-erythrocytic …

Malaria remains one of the most important infectious diseases in the world, with the greatest
burden in sub-Saharan Africa, primarily from Plasmodium falciparum infection. The …

Plasmodium parasites, the causal agents of malaria, are eukaryotic organisms that
obligately undergo sexual recombination within mosquitoes. In low transmission settings …

In The Lancet Infectious Diseases, Deus S Ishengoma and colleagues1 confirm Tanzania as
the fourth African country—alongside Rwanda, Uganda, and Eritrea—to meet the WHO …

Background Ganaplacide, also known as KAF156, is among the new antimalarial drug
candidates that have successfully reached Phase III clinical trials, and is proposed in …

Abstract Background In Africa, the first Plasmodium falciparum artemisinin partial resistance
mutation was Kelch13 (K13) 561H, detected and validated at appreciable frequency in …

Artemisinin is a truly fascinating drug in many ways. Since the unrestrained procedure of its
detection, as an antimalarial drug, artemisinin has received a great deal of consideration …

Background Artemisinin partial resistance, mediated by mutations in the Plasmodium
falciparum Kelch13 protein (K13), rapidly spread in South-East Asia (SEA), undermining …

Background Emerging artemisinin partial resistance and diagnostic resistance are a threat
to malaria control in Africa. Plasmodium falciparum kelch13 (k13) propeller-domain …